Radiotherapy combined with hormone therapy is a standard of care for prostate cancer at many stages [15], but limited information is available regarding the combination of next generation androgen-receptor signaling targeted drugs and radiohormonotherapy [16]. This evidence concerns the gene AR and Familial prostate cancer.